User: Guest  Login
Title:

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Document type:
journal article
Author(s):
Baigent, C; Landray, MJ; Reith, C; Emberson, J; Wheeler, DC; Tomson, C; Wanner, C; Krane, V; Cass, A; Craig, J; Neal, B; Jiang, L; Hooi, LS; Levin, A; Agodoa, L; Gaziano, M; Kasiske, B; Walker, R; Massy, ZA; Feldt-Rasmussen, B; Krairittichai, U; Ophascharoensuk, V; Fellström, B; Holdaas, H; Tesar, V; Wiecek, A; Grobbee, D; de Zeeuw, D; Grönhagen-Riska, C; Dasgupta, T; Lewis, D; Herrington, W; Mafham, M; Majoni, W; Wallendszus, K; Grimm, R; Pedersen, T; Tobert, J; Armitage, J; Baxter, A; Bray, C;...     »
Abstract:
Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary revascularisation in people without kidney disease, but its effects in people with moderate-to-severe kidney disease are uncertain. The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in such patients.This randomised double-blind trial included 9270 patients with chronic kidney disease (3023 on dialysis and 6247...     »
Journal title abbreviation:
Lancet
Year:
2011
Journal volume:
377
Journal issue:
9784
Pages contribution:
2181-92
Language:
eng
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/21663949
Print-ISSN:
0140-6736
TUM Institution:
Abteilung für Nephrologie
 BibTeX